REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Last updated: July 1, 2024
Sponsor: Arsenal Medical, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemorrhage

Low Blood Pressure (Hypotension)

Hyponatremia

Treatment

ResQFoam

Clinical Study ID

NCT02880163
CLIN-030
  • Ages > 15
  • All Genders

Study Summary

The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Estimated age of 15 years or older (or subject weight estimated at greater than 50kg if age is unknown)

  2. Emergent, exsanguinating hemorrhage, from abdominal source as defined by:

  • Class III or IV hemorrhagic shock or

  • Assessment of Blood Consumption (ABC) score ≥ 2

  1. Confirmation of abdominal hemorrhage by:
  • Direct visualization or

  • Positive Focused Assessment with Sonography in Trauma (FAST) or

  • Diagnostic Peritoneal Aspiration (DPA)

  1. No other known, uncontrolled active sources of hemorrhage

  2. Subject is intubated and sedated per local guidelines

  3. Decision to administer foam is made within 30 minutes of admission to the emergencydepartment.

  4. Decision made to proceed to emergent laparotomy made within 30 minutes of admissionto the emergency department.

  5. Definitive surgical care is expected to occur within three hours of foam deployment

  6. Subject must also be receiving concurrent transfusion of fluids or blood products.

Exclusion

Exclusion Criteria:

  1. Known or suspected major diaphragm injury

  2. Known or suspected untreated pneumothorax

  3. Known or suspected untreated hemothorax

  4. Known or suspected blunt or penetrating cardiac or thoracic aortic trauma

  5. Traumatic brain injury resulting in decapitation, visible brain matter or considerednon- survivable based on initial physical exam

  6. Received greater than five consecutive minutes of cardiopulmonary resuscitation inthe pre-emergency department setting

  7. Patients with Pulseless Electrical Activity

  8. Known allergy to isocyanate

  9. Known or suspected pregnancy

  10. History of prior abdominal surgery or evidence of abdominal surgery (scars)

  11. Disrupted abdominal wall that, in the opinion of the investigator would precludeResQFoam from being adequately contained within the abdominal cavity

  12. Subject in whom the abdominal aortic junctional tourniquet (AAJT) or ResuscitativeEndovascular Balloon Occlusion of the Aorta (REBOA) techniques have been used

  13. Known Prisoners

  14. Subjects with burns > 20% of total body surface area

  15. Subject/legally authorized representative/subject family member purposefully optedout of participation in the study

  16. Known Do Not Resuscitate order (DNR) or Physician Orders for Life SustainingTreatment (POLST)

  17. Known enrollment in another randomized, interventional study

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: ResQFoam
Phase:
Study Start date:
June 28, 2024
Estimated Completion Date:
July 28, 2025

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • University of Cincinnati

    Cincinnati, Ohio 45219
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.